{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:13:28Z","timestamp":1771632808606,"version":"3.50.1"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>This study summarizes passive surveillance data for adverse events following immunization (AEFI) reported to the National AEFI Surveillance System (NASS) in Zhejiang province and describes reporting trends from 2008 to 2011. AEFI reporting rates were calculated using denominator data from the Individual Immunization Information System and the Zhejiang provincial Bureau of Statistics. A total of 6,265 AEFI records were reported; the overall reporting rate was 9.2 per 100,000 doses. There were two peaks of reporting rates, which were associated mainly with the introduction of the pandemic H1N1 influenza virus vaccine (pH1N1) in 2009 and the measles-mumps vaccine (MM) campaign in 2010. The majority of the AEFI described nonserious events. Fifteen deaths were recorded, but only one was possibly related to immunization. The most frequently reported reactions were fever and injection site reaction. Vaccines distributed in Zhejiang province have proven to be generally safe. The data on AEFI surveillance provide a reference point for ongoing reporting of trends and illustrate the value of the NASS database as a surveillance tool for monitoring of AEFI.<\/jats:p>","DOI":"10.1128\/cvi.00541-12","type":"journal-article","created":{"date-parts":[[2012,12,13]],"date-time":"2012-12-13T04:56:49Z","timestamp":1355374609000},"page":"211-217","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":35,"title":["Surveillance for Adverse Events following Immunization from 2008 to 2011 in Zhejiang Province, China"],"prefix":"10.1128","volume":"20","author":[{"given":"Yu","family":"Hu","sequence":"first","affiliation":[{"name":"Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luoya","family":"Lin","sequence":"additional","affiliation":[{"name":"Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enfu","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaping","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Qi","sequence":"additional","affiliation":[{"name":"Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.vaccine.2004.01.016","article-title":"The Brighton Collaboration\u2014enhancing vaccine safety","volume":"22","author":"Bonhoeffer J","year":"2004","unstructured":"BonhoefferJ KohlK ChenR DuclosP HeijbelH HeiningerU JeffersonT LoupiE BrightonCollaboration. 2004. The Brighton Collaboration\u2014enhancing vaccine safety. Vaccine 22:2046. doi: 10.1016\/j.vaccine.2004.01.016.","journal-title":"Vaccine"},{"key":"e_1_3_2_3_2","unstructured":"World Health Organization. 2009. Fact sheet on measles 2008-2009. World Health Organization Geneva Switzerland. http:\/\/www.who.int\/mediacentre\/factsheets\/fs286\/en\/index.html."},{"key":"e_1_3_2_4_2","unstructured":"Ministry of Health People's Republic of China. 2010. Guideline for the surveillance of adverse events following immunization. Ministry of Health People's Republic of China Beijing China."},{"key":"e_1_3_2_5_2","unstructured":"Ministry of Health People's Republic of China. 2005. Ministry of Health technological standards for expanded program on immunization. Ministry of Health People's Republic of China Beijing China. http:\/\/www.gov.cn\/yjgl\/2005-10\/14\/content77713.htm."},{"key":"e_1_3_2_6_2","volume-title":"Zhejiang statistics year book","author":"Zhejiang Provincial Bureau of Statistics","unstructured":"Zhejiang Provincial Bureau of Statistics. 2008\u20132011. Zhejiang statistics year book. China Statistics Press, Zhejiang, China."},{"key":"e_1_3_2_7_2","unstructured":"World Health Organization. 2005. Adverse events following immunization (AEFI) causality assessment. World Health Organization Geneva Switzerland. http:\/\/www.who.int\/vaccines-documents\/DocsPDF05\/815.pdf."},{"key":"e_1_3_2_8_2","unstructured":"World Health Organization. 1999. Immunization safety surveillance: guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization (WPRO\/EPI\/99.01). World Health Organization Geneva Switzerland. http:\/\/www.who.int\/immunization_safety\/publications\/aefi\/en\/AEFI_WPRO.pdf."},{"key":"e_1_3_2_9_2","unstructured":"Ministry of Health People's Republic of China. 2008. Guideline for the identification of adverse reaction after immunization. Ministry of Health People's Republic of China Beijing China."},{"key":"e_1_3_2_10_2","first-page":"1","article-title":"Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)\u2014United States, 1991-2001","volume":"52","author":"Zhou W","year":"2003","unstructured":"ZhouW PoolV IskanderJK English-BullardR BallR WiseRP HaberP PlessRP MootreyG EllenbergSS BraunMM ChenRT. 2003. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)\u2014United States, 1991-2001. MMWR Surveill. Summ. 52:1\u201324. (Erratum, MMWR Morb. Mortal. Wkly. Rep. 52:113.).","journal-title":"MMWR Surveill. Summ."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1016\/S0264-410X(99)00132-2","article-title":"An overview of the Vaccine Adverse Event Reporting System (VAERS) as a surveillance system","volume":"17","author":"Singleton JA","year":"1999","unstructured":"SingletonJA LloydJC MootreyGT SaliveME ChenRT. 1999. An overview of the Vaccine Adverse Event Reporting System (VAERS) as a surveillance system. Vaccine 17:2908\u20132917.","journal-title":"Vaccine"},{"key":"e_1_3_2_12_2","first-page":"1151","article-title":"Adverse events following immunization in Germany from 1.1.2001 to 31.12.2003","volume":"47","author":"Keller-Stanislawski B","year":"2004","unstructured":"Keller-StanislawskiB HeussN MeyerC. 2004. Adverse events following immunization in Germany from 1.1.2001 to 31.12.2003. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 47:1151\u20131164.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"e_1_3_2_13_2","first-page":"259","article-title":"Annual report: surveillance of adverse events following immunisation in Australia, 2009","volume":"34","author":"Mahajan D","year":"2010","unstructured":"MahajanD RoomianiI GoldMS LawrenceGL McIntyrePB MenziesRI. 2010. Annual report: surveillance of adverse events following immunisation in Australia, 2009. Commun. Dis. Intell. 34:259\u2013276.","journal-title":"Commun. Dis. Intell."},{"key":"e_1_3_2_14_2","first-page":"117","article-title":"Adverse events temporally associated with vaccines\u20141992 report","volume":"21","author":"Bentsi E","year":"1995","unstructured":"BentsiE HardyM KochJ DuclosP. 1995. Adverse events temporally associated with vaccines\u20141992 report. Can. Commun. Dis. Rep. 21:117\u2013128.","journal-title":"Can. Commun. Dis. Rep."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0022-3476(97)70056-8","article-title":"Descriptive epidemiology of adverse events after immunization: reports to the Vaccine Adverse Event Reporting System (VAERS), 1991-1994","volume":"131","author":"Braun MM","year":"1997","unstructured":"BraunMM EllenbergSS. 1997. Descriptive epidemiology of adverse events after immunization: reports to the Vaccine Adverse Event Reporting System (VAERS), 1991-1994. J. Pediatr. 131:529\u2013535.","journal-title":"J. Pediatr."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.vaccine.2006.09.060","article-title":"Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses","volume":"25","author":"Heininger U","year":"2007","unstructured":"HeiningerU JacquetJM SchuermanL. 2007. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine 25:1055\u20131063.","journal-title":"Vaccine"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/00006454-200208000-00016","article-title":"Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids","volume":"21","author":"Jackson LA","year":"2002","unstructured":"JacksonLA CarsteBA MalaisD FroeschleJ. 2002. Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids. Pediatr. Infect. Dis. J. 21:781\u2013786.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1542\/peds.105.1.e12","article-title":"Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines","volume":"105","author":"Rennels MB","year":"2000","unstructured":"RennelsMB DeloriaMA PichicheroME LosonskyGA EnglundJA MeadeBD AndersonEL SteinhoffMC EdwardsKM. 2000. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 105:e12. doi: 10.1542\/peds.105.1.e12.","journal-title":"Pediatrics"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1071\/NB03007","article-title":"Immunisation adverse events clinics","volume":"14","author":"Wood N","year":"2003","unstructured":"WoodN. 2003. Immunisation adverse events clinics. N. S. W. Public Health Bull. 14:25\u201327.","journal-title":"N. S. W. Public Health Bull."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1056\/NEJMoa1008553","article-title":"Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China","volume":"364","author":"Liang X-F","year":"2011","unstructured":"LiangX-F LiL LiuD-W LiKL WuWD ZhuBP WangHQ LuoHM CaoLS ZhengJS YinDP CaoL WuBB BaoHH XuDS YangWZ WangY. 2011. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. N. Engl. J. Med. 364:638\u2013647.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_21_2","unstructured":"European Medicines Agency. 2009. European Medicines Agency reaffirms efficacy and safety of H1N1 pandemic vaccines. European Medicines Agency London United Kingdom. http:\/\/www.emea.europa.eu\/pdfs\/human\/press\/pr\/74870709en.pdf."},{"key":"e_1_3_2_22_2","unstructured":"Ministry of Health Labor and Welfare. 2009. The preliminary report on adverse reaction following pandemic H1N1 vaccination and estimation of immunization data in Japan. Ministry of Health Labor and Welfare Tokyo Japan. http:\/\/www.mhlw.go.jp\/bunya\/kenkou\/kekkaku-kansenshou04\/pdf\/091127-01a.pdf. (In Japanese.)"},{"key":"e_1_3_2_23_2","unstructured":"World Health Organization. 2009. Safety of pandemic vaccines: pandemic (H1N1) 2009 briefing note 16. World Health Organization Geneva Switzerland. http:\/\/www.who.int\/csr\/disease\/swineflu\/notes\/briefing_20091119\/en\/index.html."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barr\u00e9 syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977","volume":"10","author":"Schonberger LB","year":"1979","unstructured":"SchonbergerLB BregmanDJ Sullivan-BolyaiJZ KeenlysideRA ZieglerDW RetailliauHE EddinsDL BryanJA. 1979. Guillain-Barr\u00e9 syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am. J. Epidemiol. 10:105\u2013123.","journal-title":"Am. J. Epidemiol."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1001\/jama.292.20.2478","article-title":"Guillain-Barre syndrome following influenza vaccination","volume":"292","author":"Haber P","year":"2004","unstructured":"HaberP DeStefanoF AnguloFJ IskanderJ ShadomySV WeintraubE ChenRT. 2004. Guillain-Barre syndrome following influenza vaccination. JAMA 292:2478\u20132481.","journal-title":"JAMA"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00002018-200932040-00005","article-title":"Vaccines and Guillain-Barre syndrome","volume":"32","author":"Haber P","year":"2009","unstructured":"HaberP SejvarJ MikaeloffY DeStefanoF. 2009. Vaccines and Guillain-Barre syndrome. Drug Saf. 32:309\u2013323.","journal-title":"Drug Saf."},{"key":"e_1_3_2_27_2","unstructured":"SalisburyDM\nCampbellH\nEdwardsB. 1995. Measles rubella immunization campaign in England. \u2018One year on\u2019. Health Promotional Division & Medicines Control Agency Department of Health London United Kingdom."},{"issue":"6","key":"e_1_3_2_28_2","first-page":"9","article-title":"Supplementary immune condition for measles in Qinghai Province","volume":"15","author":"Zhang S","year":"2008","unstructured":"ZhangS ZhaoJ ZhuX ZhangY MaX. 2008. Supplementary immune condition for measles in Qinghai Province. Med. Pharm. J. Qinghai Province 15(6):9\u201311.","journal-title":"Med. Pharm. J. Qinghai Province"},{"issue":"5","key":"e_1_3_2_29_2","first-page":"288","article-title":"Analysis on a pilot of measles vaccine immunization activity in Guizhou Province","volume":"10","author":"Zhu Q","year":"2004","unstructured":"ZhuQ TongY ZhangD DuW. 2004. Analysis on a pilot of measles vaccine immunization activity in Guizhou Province. Chin. J. Vaccine Immun. 10(5):288\u2013291.","journal-title":"Chin. J. Vaccine Immun"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QCO.0b013e32811ebfb0","article-title":"Adverse events following immunization: perception and evidence","volume":"20","author":"Bonhoeffer J","year":"2007","unstructured":"BonhoefferJ HeiningerU. 2007. Adverse events following immunization: perception and evidence. Curr. Opin. Infect. Dis. 20:237\u2013246.","journal-title":"Curr. Opin. Infect. Dis."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2105\/AJPH.85.12.1706","article-title":"The reporting sensitivities of two passive surveillance systems of vaccine adverse events","volume":"85","author":"Rosenthal S","year":"1995","unstructured":"RosenthalS ChenR. 1995. The reporting sensitivities of two passive surveillance systems of vaccine adverse events. Am. J. Public Health 85:1706\u20131709.","journal-title":"Am. J. Public Health"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00541-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00541-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:48:37Z","timestamp":1627591717000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00541-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1128\/CVI.00541-12"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00541-12","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"2012-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-12-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-01-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}